Bright Minds Biosciences Inc.DRUGNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

globenewswire.com

Bright Minds Biosciences to Present at Upcoming Conferences

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

defenseworld.net

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target

globenewswire.com

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities sold in this Offering were offered by Bright Minds.

globenewswire.com

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds.

seekingalpha.com

Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

Bright Minds Biosciences remains a "Strong Buy" after positive phase 2 data for BMB-101 in drug-resistant epilepsies. DRUG's BMB-101 achieved -73.1% and -63.3% median seizure reductions in Absence Epilepsy and DEE cohorts, respectively. Multiple 2026 catalysts include additional phase 2 data, phase 3 trial initiation, and a phase 2 PWS study for BMB-101.

globenewswire.com

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “Offering”). In connection with the Offering, the Company intends to grant to the underwriters, a 30-day option to purchase up to an additional 15% of the Common Shares issued in the Offering.

benzinga.com

New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday

Bright Minds Biosciences Inc. (NASDAQ: DRUG) stock is trading higher on Tuesday after the company shared topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE).

globenewswire.com

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating BMB-101, a selective 5-HT2C biased agonist, in adult patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies. The study met its primary efficacy endpoints in both cohorts, demonstrating robust seizure reduction with a favorable safety and tolerability profile.

proactiveinvestors.com

Bright Mind Biosciences shares surge on positive epilepsy drug trial results

Shares of Bright Minds Biosciences Inc (NASDAQ: DRUG, CSE:DRUG) jumped almost 25% after the company announced positive topline results from its Phase 2...

globenewswire.com

Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

– Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after the event by visiting the “Investors” section of the Company's website and selecting “Events and Presentations.

defenseworld.net

Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% Higher – Here’s What Happened

Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report)'s share price rose 4.2% during trading on Wednesday. The company traded as high as $78.40 and last traded at $79.0010. Approximately 43,697 shares traded hands during mid-day trading, a decline of 47% from the average daily volume of 82,167 shares. The stock had previously closed

defenseworld.net

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bright Minds Biosciences Inc. (NASDAQ: DRUG - Get Free Report) have received an average rating of "Buy" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation

proactiveinvestors.com

Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials

For three decades, central nervous system (CNS) drug development was a tough space for investors, scarred by failed bets on Alzheimer's disease, plateauing first-generation antidepressants, and setbacks in safety and efficacy. But advances in receptor-selective chemistry and so-called “biased agonism” – steering toward therapeutic pathways and away from areas that cause side effects – are reviving interest in the field.

zacks.com

Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why

Bright Minds Biosciences Inc. (DRUG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

globenewswire.com

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will participate in the following upcoming events:

zacks.com

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in Bright Minds Biosciences Inc. (DRUG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

fool.com

Why Bright Minds Biosciences Stock Topped the Market on Monday

Days after starting a new investigational program, it announced four appointments to its scientific advisory board. All of these professionals are experts in the affliction being targeted.

globenewswire.com

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 -- NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today announced the addition of four global experts in Prader-Willi Syndrome (PWS) to its Scientific Advisory Board (SAB):

globenewswire.com

Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with Prader-Willi Syndrome -- -- Key Opinion Leaders (KOLs) participating on the call will include Theresa V. Strong, PhD., Jennifer L. Miller, MD, and Elizabeth Roof, H.S.P., M.A. -- -- Strong pre-clinical and clinical rationale supports potential of BMB 5-HT2C agonists to be the first on-target mechanism addressing both neuropsychiatric symptoms and hyperphagia -- NEW YORK and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today announced the initiation of its Prader-Willi Syndrome (PWS) program, and nomination of BMB-105 as a new clinical candidate. As part of the development program, Bright Minds will commence:

zacks.com

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance